medwireNews: The monarchE investigators have identified baseline factors linked to an increased risk for discontinuation of abemaciclib in the trial comprising patients with hormone receptor-positive, HER2-negative early breast cancer.
medwireNews: Plasma circulating tumor (ct)DNA analysis could help identify patients with hormone receptor (HR)-positive, HER2-negative early breast cancer who are likely to have distant recurrence at 5 years or more after diagnosis despite receipt of adjuvant therapy, indicate CHiRP study results.
medwireNews: Combining clinicopathologic factors with the luminal A subtype could help identify women with a very low risk for breast cancer local recurrence after breast-conserving surgery, making them good candidates for adjuvant radiotherapy omission, suggests the LUMINA study.
LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC)
LUMINA efficacy presentation from ASCO 2022, Chicago
Expert discussion with Nadia Harbeck and Stephen Johnston featuring the ADAPT and POETIC trials
medwireNews: Two subgroup analyses from the monarchE study confirm the benefit of supplementing adjuvant endocrine therapy (ET) with the CDK4/6 inhibitor abemaciclib in people with hormone receptor-positive, HER2-negative early breast cancer at high risk for recurrence.
medwireNews: A single dose of patritumab deruxtecan (HER3-DXd) elicits a “clinically meaningful” response in previously untreated patients with hormone receptor (HR)-positive, HER2-negative early breast cancer, the SOLTI TOT-HER3 investigators have found.
medwireNews: Using the 21-gene recurrence score (RS) in conjunction with response to preoperative endocrine therapy (ET) could help to spare adjuvant chemotherapy in certain pre- and postmenopausal patients with hormone receptor (HR)-positive, HER2-negative early breast cancer, suggest findings from the WSG-ADAPT umbrella trial.